<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01596257</url>
  </required_header>
  <id_info>
    <org_study_id>12-016</org_study_id>
    <nct_id>NCT01596257</nct_id>
  </id_info>
  <brief_title>Bulk Versus Fractionated Stem Cell Infusions in Patients With Hematologic Malignancies Undergoing Stem Cell Transplantation</brief_title>
  <official_title>Randomized Phase II Trial of Bulk Versus Fractionated Stem Cell Infusions in Patients With Hematologic Malignancies Undergoing Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out if getting a blood stem cell transplant with donor&#xD;
      stem cells given over several days is better than getting a blood stem cell transplant with&#xD;
      donor stem cells given over 1 day. We want to find out which procedure over will result in&#xD;
      improved recovery of blood and immune function after transplant. When donor stem cells are&#xD;
      given over various days in mice, the blood and immune system recovery is quicker.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a complex study that involves various interventions, Intervention #1: Donor Initial&#xD;
      Stem Cell Collection; Intervention #2: Stem Cell Product Initial Processing Orders;&#xD;
      Intervention #3 Patient Admission and Transplantation; Intervention #4: Stem cell infusion;&#xD;
      Intervention #5: Post infusion follow up; Intervention #6: Off Study Patient and Donor&#xD;
      Evaluation.&#xD;
&#xD;
      Patients whose donor fails to collect the appropriate number of cells will receive all their&#xD;
      cells as a bulk infusion. These patients will continue to receive a transplant on protocol&#xD;
      but will be replaced until both arms have reached the target accrual.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 5, 2012</start_date>
  <completion_date type="Actual">August 30, 2021</completion_date>
  <primary_completion_date type="Actual">August 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>neutrophil recovery</measure>
    <time_frame>2 years</time_frame>
    <description>Determine the effects of fractionated vs. bulk stem cell infusions on neutrophil recovery as defined by number of days with an absolute neutrophil count of less than 500 neutrophils per micro liter and time to an absolute neutrophil count (ANC) of 500.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>safety</measure>
    <time_frame>2 years</time_frame>
    <description>Toxicities will be graded on a scale of 0 to 4 as described by the NCI-Common Terminology for Adverse Events (CTCAE), version 4.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>immune- reconstitution</measure>
    <time_frame>1 year</time_frame>
    <description>The area under the hematopoietic recovery curve for the factors: ALC, CD4, CD8, and platelet count. The area under the curve will be computed based on recordings at days 30, 60, 100, 180, 365.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>on bacterial, viral, and fungal infections during the first 100 days post transplant</measure>
    <time_frame>100 days post days transplant</time_frame>
    <description>The time to ALC 500, and the time to first bacterial, viral, and fungal infection will be computed using the cumulative incidence function and a comparison between groups will be undertaken using Gray's test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hematopoietic function</measure>
    <time_frame>up to 1 year</time_frame>
    <description>Determine the effect of fractionated vs bulk CD34 selected stem cell infusions on hematopoietic function as determined by platelet counts and cumulative platelet transfusion requirements on days 30, 60 and 100, 6 and 12 months post transplant.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">127</enrollment>
  <condition>Leukemia</condition>
  <arm_group>
    <arm_group_label>bulk SCT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive reduced intensity or myeloablative conditioning regimen, GVHD prophylaxis, and undergo T cell depleted or no T cell depleted allogeneic SCT on day 0. After completion of study treatment, patients are followed up every 6-8 weeks for up to 24 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>fractionated SCT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive reduced intensity or myeloablative conditioning regimen, GVHD prophylaxis, and undergo T cell depleted or no T cell depleted allogeneic SCT on days 0, 2, 4, and 6. After completion of study treatment, patients are followed up every 6-8 weeks for up to 24 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic hematopoietic stem cell transplantation</intervention_name>
    <description>Undergo allogeneic hematopoietic stem cell transplant</description>
    <arm_group_label>bulk SCT</arm_group_label>
    <arm_group_label>fractionated SCT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CliniMACS</intervention_name>
    <arm_group_label>bulk SCT</arm_group_label>
    <arm_group_label>fractionated SCT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who are considered candidates for an allogeneic stem cell transplantation as&#xD;
             treatment for any of the following hematologic disorders:&#xD;
&#xD;
          -  Acute Leukemia&#xD;
&#xD;
          -  Myelodysplastic syndrome&#xD;
&#xD;
          -  Other myeloproliferative disorder (i.e. myelofibrosis, chronic myelomonocytic&#xD;
             leukemia, or chronic myelogenous leukemia)&#xD;
&#xD;
          -  Non Hodgkins Lymphoma&#xD;
&#xD;
          -  Hodgkins Disease&#xD;
&#xD;
          -  Multiple Myeloma&#xD;
&#xD;
          -  Age includes from birth to &lt; 75 years old.&#xD;
&#xD;
          -  Patients must have a Karnofsky (adult) or Lansky (pediatric) Performance Status &gt; 70%&#xD;
&#xD;
          -  Patients must have adequate organ function measured by:&#xD;
&#xD;
          -  Cardiac: asymptomatic or if symptomatic then LVEF at rest must be &gt; 40%&#xD;
&#xD;
          -  Hepatic: &lt; 5x ULN ALT and &lt; 1.5 total serum bilirubin, unless there is congenital&#xD;
             benign hyperbilirubinemia.&#xD;
&#xD;
          -  Renal: serum creatinine &lt;1.5 mg/dl or if serum creatinine is outside the normal range,&#xD;
             then CrCl &gt; 40 ml/min (measured or calculated/estimated)&#xD;
&#xD;
          -  Pulmonary: asymptomatic or if symptomatic, DLCO &gt; 40% of predicted (corrected for&#xD;
             hemoglobin).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Female patients who are pregnant or breast-feeding.&#xD;
&#xD;
          -  Active viral, bacterial or fungal infection&#xD;
&#xD;
          -  Patient seropositive for HIV-I/II; HTLV -I/II&#xD;
&#xD;
          -  Presence of leukemia in the CNS&#xD;
&#xD;
          -  Candidate for a protocol of higher priority. For the purpose of this study, the&#xD;
             following protocols will be considered of higher priority: 10-051&#xD;
&#xD;
        Donor Inclusion Criteria:&#xD;
&#xD;
          -  HLA compatible related or unrelated donor, (i.e. a fully matched unmanipulated grafts&#xD;
             or 1-2 HLA allele disparate donor for CD34 selected grafts).&#xD;
&#xD;
          -  Meets criteria outlined in the FACT-approved SOP for &quot;DONOR EVALUATION AND SELECTION&#xD;
             FOR ALLOGENEIC TRANSPLANTATION&quot; in the Blood and Marrow Transplant Program Manual,&#xD;
             document E-1 see http://mskweb5.mskcc.org/intranet/html/80312.cfm&#xD;
&#xD;
          -  Donor must have adequate peripheral venous catheter access for leukapheresis or must&#xD;
             agree to placement of a central catheter.&#xD;
&#xD;
          -  Wt &gt;25kg&#xD;
&#xD;
        Donor Exclusion Criteria:&#xD;
&#xD;
          -  Evidence of active infection (including urinary tract infection, or upper respiratory&#xD;
             tract Infection) or viral hepatitis exposure (on screening), unless only HBS Ab+ and&#xD;
             HBV DNA negative.&#xD;
&#xD;
          -  Medical or physical reason which makes the donor unlikely to tolerate or cooperate&#xD;
             with growth factor therapy and leukapheresis.&#xD;
&#xD;
          -  Factors which place the donor at increased risk for complications from leukapheresis&#xD;
             or GCSF therapy (e.g., autoimmune disease, sickle cell trait, symptomatic coronary&#xD;
             artery disease requiring therapy).&#xD;
&#xD;
          -  Pregnancy (positive serum or urine Î²-HCG) or breastfeeding. Women of childbearing age&#xD;
             must avoid becoming pregnant while on the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sergio Giralt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org/</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>May 9, 2012</study_first_submitted>
  <study_first_submitted_qc>May 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2012</study_first_posted>
  <last_update_submitted>August 31, 2021</last_update_submitted>
  <last_update_submitted_qc>August 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CliniMACS-CD34 Reagent System</keyword>
  <keyword>Acute Leukemia</keyword>
  <keyword>Myelodysplastic syndrome</keyword>
  <keyword>Non Hodgkins Lymphoma</keyword>
  <keyword>Hodgkins Disease</keyword>
  <keyword>Multiple Myeloma</keyword>
  <keyword>12-016</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

